C 4
X D

23 December 2025

Dear Shareholder,

On behalf of the Board, I wanted to provide a short update on the business before the end of 2025.

We've had an extremely busy year on all fronts. It was great to receive an anticipated milestone payment from one of our partnered programs earlier this year, and to make further positive progress on three of our unpartnered programs. A highlight was selecting a potential best-in-class once-daily development candidate from our most advanced program, alpha4 beta7; the associated press release stimulated significant interest from potential partners.

I'm also pleased to say that 2025 has seen relative stability at the Board and senior leadership level.

In the spring we tested market appetite to fund our programs into clinical development, as per the strategy set out in September 2024. Whilst we received significant interest and indeed notes of interest to participate in such a fundraising, we could not secure a lead funder. This was of course disappointing, although not surprising given the state of the biotech capital markets for the past two years or so. Our area of focus (Inflammation and Immunology) remains a very attractive segment of the industry, however, so we are continuing to monitor the investment environment carefully.

Without a fundraise we, of course, reviewed our strategy, in consultation with our main shareholders.

We also reinvigorated our business development activities in Q1 to assess potential pre-clinical partnering interest in our programs. Feedback again was positive in terms of our targets, but it was also clear that our programs needed to be at a more advanced stage to be more attractive to partners. Therefore, in order to focus resources and keep advancing three of our unpartnered programs, we paused our STAT6 program and took the difficult decision to significantly reduce our operating costs including a headcount reduction.

As a result, we now have a very lean team in place that can work across the projects, with all of our scientific activity being aligned to commercial discussions with partners. I'm pleased to report that we have multiple ongoing discussions and the Board is optimistic that we can reach at least one new deal in the first half of 2026.

As regards our existing partnerships, we expect updates during Q1 2026. Both programs have progressed during 2025 and we are hopeful that they will generate further returns to C4XD.

On 1st December James Ede-Golightly joined as a non-executive director, replacing Richard Jones. I'd like to thank Richard for his contributions and to welcome James to the Board where he will represent Ora Capital.

James co-founded ORA in 2006 having started his career at Mercury Asset Management (now Blackrock). He has extensive experience as a board director and was awarded Chartered Director of the year in 2012 by the IoD. James brings valuable experience to the Board and will be chairing the remuneration committee as well as bringing enhanced focus on governance and board effectiveness.

We plan to further review the Board composition and arrangements during Q1 of 2026 – this will be informed by commercial progress as well as the Company's plans to start to return cash to shareholders, as previously communicated. Overall feedback from many shareholders has been supportive of the Company's new strategy including praise for the leadership team regarding the cost reductions and progress of our programs.

One further point to note: after delisting from the AIM market in 2024, we established a matched bargain facility through Asset Match, to enable Shareholders to trade ordinary shares. Due to very low demand levels, and also to reduce costs, we have decided to cease this facility as of the end of February 2026. As a result, there will be one further trading window, during February 2026. If you wish to trade I would encourage you to take the opportunity during this auction.

Finally, I'd like to thank Emma and Nick in particular for all their hard work this year. Advancing our programs and implementing restructures has been extremely challenging. I'm sure that I can speak for all shareholders in recognising their efforts.

I wish you well for 2026 and thank you for your ongoing support.

Faithfully yours,



David Lawrence
Chairman